<DOC>
	<DOCNO>NCT03008421</DOCNO>
	<brief_summary>In present study , investigator aim evaluate potential oral probiotic , contain Lactobacillus strain , eradicate reduce vaginal colonization group B Streptococcus ( GBS ) pregnancy . This could help prevent neonatal morbidity mortality reduce risk neonatal sepsis , pneumonia , meningitis , know early-onset late-onset GBS infection .</brief_summary>
	<brief_title>Oral Probiotics Reduce Vaginal Group B Streptococcal Colonization Late Pregnancy</brief_title>
	<detailed_description>The group B Streptococcus ( GBS ) Streptococcus agalactiae gram-positive bacterium present 10-30 % healthy female population ( 1 ) . Throughout pregnancy intrapartum period , maternal colonization GBS lead vertical transmission bacterium infant . This result neonatal sepsis , pneumonia , meningitis , know early-onset GBS infection , well maternal urinary tract infection , arthritis , pneumonia ( 2 ) . Various strategy test prevent GBS infection . The antenatal GBS screen successfully prove identify colonized woman , receive intrapartum antimicrobial prophylaxis . This strategy lead substantial reduction incidence neonatal sepsis almost 80 % ( 3 ) . As result , general use GBS screening integrate US-American recommendation , since screen superior risk-related procedure , compare rate early-onset neonatal sepsis ( 4 ) . Later , GBS screen also become part recommendation European Consensus Conference ( 3 ) . The urogenital microflora healthy woman comprise approximately 50 specie organisms , differ composition accord exposure several factor . The flora pregnant woman dominate variety Lactobacillus specie , play essential role protect genital infection ( 5 ) . A deficiency lactobacillus upset microbial balance vagina , may result increased susceptibility colonization pathogens GBS ( 6 ) . As demonstrated Gardnerella vaginalis , Lactobacillus strain disrupt biofilm pathogen in-vitro setting , inhibits growth ( 7 ) . This lead use probiotic populate vagina , order prevent treat infection . The supplementation probiotic contain Lactobacillus strain later proven improve cure rate prevent recurrent infection ( 8 ) . At Department , pregnancy care include prenatal consultation , woman register plan delivery 10 + 0 ( 10 week plus 0 day ) 16 + 0 ( 16 week plus 0 day ) gestational week . During consultation , undergo routine screen asymptomatic vaginal infection Gram-stained analysis vaginal flora ( 9 ) . In case vaginal infection , undergo follow-up smear 4-6 week . Routine pregnancy care perform outpatient gynecologist ' office , follow Austrian government 's welfare program , document official mother-child booklet . This national pregnancy care program use health precaution woman fetus include obligatory examination predetermine point ( 10 ) . European guideline recommend antenatal screen vaginal colonization group B Streptococcus ( GBS ) 35 + 0 37 + 0 gestational week , perform demand outpatient gynecologist , routinely cover social health insurance Austria ( 3 ) . During routine registration delivery Department , woman ask participate study . Assessment eligibility perform woman ( ) singleton pregnancy , ( ii ) without imminent miscarriage , ( iii ) without recently undergone antibiotic probiotic treatment . After informed consent , study participant ask present 34 + 0 36 + 0 gestational week first study visit . At visit , CDC-recommended combine vaginal-to-rectal swab take introitus vagina anorectum . The combined incubation know increase detection rate GBS 30 % ( 11 ) . Sterile swab obtain vaginal fluid collection lateral vaginal wall posterior fornix vagina , follow insertion anal sphincter . For culture base method , apply transport medium subsequently inoculate microbiological laboratory . After inoculation , selective enrichment broth use ( TransVag Broth ) , follow incubation 18 24 hour . That follow subculture use selective medium another 18 24 hour . If colony present , undergo extraction determine Group A B streptococcus present ( 12 , 13 ) . The threshold GBS positive result consider great 102 colony-forming unit ( CFU ) per swab . In case negative GBS screen result , woman exclude study . In case positive GBS screening result , woman randomize verum placebo group . The study follow prospective randomize placebo-controlled double-blinded mono-centric design . Randomization perform use Randomizer® ( Institute Medical Informatics , Statistics Documentation , Medical University Graz ) , web-based patient randomization service clinical trial . Women assign verum group receive patent dietary supplement four viable lactobacillus strain ( Astarte® , Pizeta Pharma S.p.a. , Ponte San Giovanni , Italy ) , contain Lactobacillus crispatus Lbv88 , Lactobacillus rhamnosus Lbv96 , Lactobacillus jensenii Lbv116 , Lactobacillus gasseri Lbv150 . This supplementation proven transmigrate intestinal lumen vaginal area , act microbial ecosystem barrier effect pathogenic microorganism , symptom related dysbiosis recurrent infection relieve even prevent ( 14-16 ) . Supplementation include twice daily ( morning/evening ) oral intake 14 day . Women placebo group receive identical-looking oral potato-maltodextrin-based placebo , also give twice daily ( morning/evening ) 14 day . Patients , investigator , microbiological staff blind treatment assignment . The composition study medication follow : L.crispatus Lbv88 ( DSM 22566 ) 1 x 10^9 Guaranteed viable cell count ( CFU/dose ) , L. rhamnosus Lbv96 ( DSM 22560 ) 1 x 10^9 CFU/dose , L. jensenii Lbv116 ( DSM 22567 ) 0.2 x 10^9 CFU/dose , L. gasseri Lbv150N ( DSM 22583 ) 0.3 x 10^9 CFU/dose , Potato maltodextrin , Insoluble dietary fibre , Silicium dioxide . From participant , consecutive vaginal swab take second study visit 36 + 0 38 + 0 gestational week ( i.e. , 2 week first study visit ) . Sterile swab obtain inoculate previously describe . In case positive GBS screening result , ( ) patient subsequently inform , result document ( ii ) mother-child booklet ( iii ) PIA Fetal Database , version 5.6.16.917 ( General Electric Company , GE Viewpoint , Munich , Germany ) . This procedure necessary ensure intrapartum penicillin treatment , follow current guideline routine practice ( 2 ) . During study visit , vaginal swab also take perform Gram-stained analysis vaginal flora , order exclude woman acute infection ( i.e. , bacterial vaginosis , trichomoniasis , candidiasis ) study visit 1 , gain information flora . The primary endpoint study recovery GBS negative state . Secondary endpoint include ( ) rate early-onset neonatal sepsis ( postnatal age le 7 day ) , ( ii ) rate late-onset neonatal sepsis ( postnatal age 7 day ) , ( iii ) gestational age delivery , record term delivery 37 + 0 gestational week , ( iv ) rate preterm delivery , define delivery 36 + 6 gestational week , ( v ) neonatal birthweight , define weight time delivery , ( vi ) rate live birth , defined term preterm delivery infant Apgar score 1 minute &gt; 0 , ( vii ) mode delivery ( i.e. , spontaneous vaginal birth , cesarean section , instrumental vaginal delivery ) . Per day , approximately 10 patient undergo routine registration delivery department . All assessed eligibility study . Approximately 60 % patient present normal vaginal flora without infection , would lead number 6/10 potentially eligible patient per day . A systematic review prevalence maternal GBS colonization Europe report rate range 6.5 % 36 % . The carriage rate vary Eastern Europe 19.7 % 29.3 % , Western Europe 11 % 21 % , Scandinavia 24.3 % 36 % , Southern Europe 6.5 % 32 % ( 17 ) . The investigator therefore conclude GBS colonization rate within obstetric population approximately 25 % . This lead number 1.5/6 potentially eligible patient per day , could assign randomization . The power present study calculate use dichotomize endpoint : recovery y/n . ( i.e. , defined GBS negative ) . For sample size calculation , investigator assume 43 % woman verum group achieve primary endpoint ( i.e. , recovery GBS negative state ) . This calculation base previously publish clinical preclinical data ( 18-20 ) . The investigator expect 18 % recovery rate placebo group . Under assumption , Chi-Squared test two-sided significance level α = 0.05 90 % power detect group difference sample N = 70 per group . With regard drop-out rate 10 % , investigator therefore need screen N = 1040 study visit 1 , would lead 624/1040 ( 60 % ) patient without infection , 156/624 ( 25 % ) GBS-positive . Out , N = 78 per group randomize , would lead N = 70 per group estimate drop-out 10 % . The investigator need 9-12 month screen 1040 patient study inclusion . References : 1 . Verani JR , McGee L , Schrag SJ , Division Bacterial Diseases NCfI , Respiratory Diseases CfDC , Prevention . Prevention perinatal group B streptococcal disease -- revise guideline CDC , 2010 . MMWR Recommendations report : Morbidity mortality weekly report Recommendations report . 2010 Nov 19 ; 59 ( RR-10 ) :1-36 . PubMed PMID : 21088663 . 2 . Ohlsson A , Shah VS. Intrapartum antibiotic know maternal Group B streptococcal colonization . The Cochrane database systematic review . 2014 Jun 10 ( 6 ) : CD007467 . PubMed PMID : 24915629 . 3 . Di Renzo GC , Melin P , Berardi A , Blennow M , Carbonell-Estrany X , Donzelli GP , et al . Intrapartum GBS screen antibiotic prophylaxis : European consensus conference . The journal maternal-fetal &amp; neonatal medicine : official journal European Association Perinatal Medicine , Federation Asia Oceania Perinatal Societies , International Society Perinatal Obstet . 2015 May ; 28 ( 7 ) :766-82 . PubMed PMID : 25162923 . 4 . Schrag SJ , Zell ER , Lynfield R , Roome A , Arnold KE , Craig AS , et al . A population-based comparison strategy prevent early-onset group B streptococcal disease neonate . The New England journal medicine . 2002 Jul 25 ; 347 ( 4 ) :233-9 . PubMed PMID : 12140298 . 5 . Spiegel CA , Amsel R , Eschenbach D , Schoenknecht F , Holmes KK . Anaerobic bacteria nonspecific vaginitis . The New England journal medicine . 1980 Sep 11 ; 303 ( 11 ) :601-7 . PubMed PMID : 6967562 . 6 . Forsum U , Holst E , Larsson PG , Vasquez A , Jakobsson T , Mattsby-Baltzer I. Bacterial vaginosis -- microbiological immunological enigma . APMIS : acta pathologica , microbiologica , et immunologica Scandinavica . 2005 Feb ; 113 ( 2 ) :81-90 . PubMed PMID : 15723682 . 7 . Saunders S , Bocking A , Challis J , Reid G. Effect Lactobacillus challenge Gardnerella vaginalis biofilms . Colloids surface B , Biointerfaces . 2007 Apr 01 ; 55 ( 2 ) :138-42 . PubMed PMID : 17234391 . 8 . Rayes N , Seehofer D , Hansen S , Boucsein K , Muller AR , Serke S , et al . Early enteral supply lactobacillus fiber versus selective bowel decontamination : control trial liver transplant recipient . Transplantation . 2002 Jul 15 ; 74 ( 1 ) :123-7 . PubMed PMID : 12134110 . 9 . Farr A , Kiss H , Hagmann M , Marschalek J , Husslein P , Petricevic L. Routine Use Antenatal Infection Screen-and-Treat Program Prevent Preterm Birth : Long-Term Experience Tertiary Referral Center . Birth . 2015 Jun ; 42 ( 2 ) :173-80 . PubMed PMID : 25677078 . 10 . Sperno R , Rudelstorfer R , Gruber W. [ Effect prenatal care general practice clinic course pregnancy labor ] . Wiener medizinische Wochenschrift . 1985 Feb 15 ; 135 ( 3 ) :65-9 . PubMed PMID : 3984353 . Einfluss der pranatalen Betreuung Praxis und Klinik auf den Schwangerschafts- und Geburtsverlauf . 11 . American College O , Gynecologists Committee Obstetric P. ACOG Committee Opinion No . 485 : Prevention early-onset group B streptococcal disease newborn . Obstetrics gynecology . 2011 Apr ; 117 ( 4 ) :1019-27 . PubMed PMID : 21422882 . 12 . Baker CJ , Clark DJ , Barrett FF . Selective broth medium isolation group B streptococci . Applied microbiology . 1973 Dec ; 26 ( 6 ) :884-5 . PubMed PMID : 4588195 . Pubmed Central PMCID : 379927 . 13 . Larsen JW , Sever JL . Group B Streptococcus pregnancy : review . American journal obstetrics gynecology . 2008 Apr ; 198 ( 4 ) :440-8 ; discussion 8-50 . PubMed PMID : 18201679 . 14 . Kiss H , Kogler B , Petricevic L , Sauerzapf I , Klayraung S , Domig K , et al . Vaginal Lactobacillus microbiota healthy woman late first trimester pregnancy . BJOG : international journal obstetrics gynaecology . 2007 Nov ; 114 ( 11 ) :1402-7 . PubMed PMID : 17877778 . 15 . Kaufmann U , Domig KJ , Lippitsch CI , Kraler M , Marschalek J , Kneifel W , et al . Ability orally administer lactobacilli preparation improve quality neovaginal microflora male female transsexual woman . European journal obstetrics , gynecology , reproductive biology . 2014 Jan ; 172:102-5 . PubMed PMID : 24239295 . 16 . Domig KJ , Kiss H , Petricevic L , Viernstein H , Unger F , Kneifel W. Strategies evaluation selection potential vaginal probiotic human source : exemplary study . Beneficial microbe . 2014 Sep ; 5 ( 3 ) :263-72 . PubMed PMID : 24675230 . 17 . Barcaite E , Bartusevicius A , Tameliene R , Kliucinskas M , Maleckiene L , Nadisauskiene R. Prevalence maternal group B streptococcal colonisation European country . Acta obstetricia et gynecologica Scandinavica . 2008 ; 87 ( 3 ) :260-71 . PubMed PMID : 18307064 . 18 . Ho M , Chang YY , Chang WC , Lin HC , Wang MH , Lin WC , et al . Oral Lactobacillus rhamnosus GR-1 Lactobacillus reuteri RC-14 reduce Group B Streptococcus colonization pregnant woman : A randomized control trial . Taiwanese journal obstetrics &amp; gynecology . 2016 Aug ; 55 ( 4 ) :515-8 . PubMed PMID : 27590374 . 19 . De Gregorio PR , Juarez Tomas MS , Leccese Terraf MC , Nader-Macias ME . Preventive effect Lactobacillus reuteri CRL1324 Group B Streptococcus vaginal colonization experimental mouse model . Journal apply microbiology . 2015 Apr ; 118 ( 4 ) :1034-47 . PubMed PMID : 25786121 . 20 . Reid JN , Bisanz JE , Monachese M , Burton JP , Reid G. The rationale probiotic improve reproductive health pregnancy outcome . American journal reproductive immunology . 2013 Jun ; 69 ( 6 ) :558-66 . PubMed PMID : 23414386 .</detailed_description>
	<mesh_term>Pregnancy Complications</mesh_term>
	<criteria>Pregnant woman btw . 34 + 0 36 + 0 gestational week GBS positive GBS screening ( study visit 1 ) No current vaginal infection ( i.e. , Nugent score 06 w/o pathogen study visit 1 ) Multiple pregnancy Vaginal bleeding Current vaginal infection ( i.e. , bacterial vaginosis , chlamydia , trichomoniasis , candidiasis others ) Antibiotics &lt; 4 week randomization Probiotics &lt; 4 week randomization</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>